OncoMatch/Clinical Trials/NCT04644016
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Is NCT04644016 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for aml.
Treatment: Clofarabine · Fludarabine · Busulfan · Cyclosporine-A · Mycophenolate Mofetil · Cord Blood Graft — This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Demographics
Prior therapy
Cannot have received: autologous stem cell transplant
Exception: allowed if > 6 months prior
Autologous stem cell transplant within the preceding 6 months
Cannot have received: allogeneic stem cell transplant
Any prior allogeneic stem cell transplant
Lab requirements
Blood counts
MDS/MPD patients must have less than 10% bone marrow myeloblasts and ANC ≥ 0.2 (growth factor supported if necessary) at transplant work-up
Kidney function
serum creatinine ≤ 1.5x normal for age. If serum creatinine is outside the normal range, then CrCl > 50 mL/min/1.73m2 (calculated or estimated) or GFR (mL/min/1.72m2) >30% of predicted normal for age
Liver function
Bilirubin ≤ 1.5 mg/dL (unless benign congenital hyperbilirubinemia); ALT ≤ 3 x upper limit of normal
Cardiac function
Left ventricular ejection fraction ≥ 50%
Bilirubin ≤ 1.5 mg/dL (unless benign congenital hyperbilirubinemia). ALT ≤ 3 x upper limit of normal. Pulmonary function (spirometry and corrected DLCO) ≥ 50% predicted (corrected for hemoglobin). Left ventricular ejection fraction ≥ 50%. Age-adjusted Hematopoietic Cell Transplantation-Comorbidity Index (aaHCT-CI) ≤ 7. Renal: serum creatinine ≤ 1.5x normal for age. If serum creatinine is outside the normal range, then CrCl > 50 mL/min/1.73m2 (calculated or estimated) or GFR (mL/min/1.72m2) >30% of predicted normal for age.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04644016 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous stem cell transplant, allogeneic stem cell transplant disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 21 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify